Drug Interactions With Excessive Daytime Sleepiness Treatments
Abstract
Objective: To evaluate the potential for drug interactions with pharmacotherapy for central hypersomnolence (modafinil, armodafinil, solriamfetol, pitolisant, sodium oxybate, methylphenidate, amphetamine, lithium, clarithromycin). Data Sources: A systemic literature search (1980 to June 2025) was performed using PUBMED, SCOPUS, and EMBASE to locate relevant articles. The MeSH terms included specific medication and "drug interactions." DAILYMED was used for product-specific interactions. Study Selection and Data Extraction: The search was conducted to identify drug interactions with excessive daytime sleepiness treatments. The search was limited to those articles studying humans and publications using the English language. Case reports, clinical trials, review articles, treatment guidelines, and package labeling were selected for inclusion. Data Synthesis: Primary literature and package labeling indicate that pharmacotherapy for central hypersomnolence is subject to both pharmacokinetic and pharmacodynamic interactions. While some interactions can be clinically significant, much of the data available for potential drug interactions was found in the package labeling and not from the primary literature. Conclusions: Available literature indicates that pharmacotherapy for central hypersomnolence is associated with clinically significant drug interventions and subsequent possible adverse reactions. Clinicians in all practice settings should be mindful of the potential to minimize…
Read the paper
Related studies
- The Matrisome: In Silico Definition and In Vivo Characterization by Proteomics of Normal and Tumor Extracellular Matrices
- The Escherichia coli MG1655 in silico metabolic genotype: Its definition, characteristics, and capabilities
- In silico pharmacology for drug discovery: methods for virtual ligand screening and profiling
- In silico prediction of splice-altering single nucleotide variants in the human genome
- In silico clinical trials: how computer simulation will transform the biomedical industry
- In silico optimization of a guava antimicrobial peptide enables combinatorial exploration for peptide design
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.